Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PYL005
MIFTS: 56

Pyelonephritis

Categories: Nephrological diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Pyelonephritis

About this section

MalaCards integrated aliases for Pyelonephritis:

Name: Pyelonephritis 12 74 29 54 43 15 17 71

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:11400
ICD9CM 34 590.80
MeSH 43 D011704
NCIt 49 C34965
SNOMED-CT 67 45816000
ICD10 32 N10-N16 N12 N16
UMLS 71 C0034186
Sources

Summaries for Pyelonephritis

About this section
MalaCards based summary : Pyelonephritis is related to chronic pyelonephritis and acute pyelonephritis. An important gene associated with Pyelonephritis is TLR4 (Toll Like Receptor 4), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs leucovorin and Trimethoprim have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and prostate, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 74 Pyelonephritis is inflammation of the kidney, typically due to a bacterial infection. Symptoms most... more...

Sources

Related Diseases for Pyelonephritis

About this section

Diseases in the Pyelonephritis family:

Chronic Pyelonephritis Acute Pyelonephritis

Diseases related to Pyelonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1024)
# Related Disease Score Top Affiliating Genes
1 chronic pyelonephritis 33.9 UMOD TLR4 CALCA ALB ACE
2 acute pyelonephritis 32.8 NAGLU LCN2 IL6 IL10 GPT CXCR2
3 cystitis 32.2 UMOD TNF TLR4 IL6 CXCL8 CRP
4 vesicoureteral reflux 1 31.8 UMOD NAGLU LCN2 CXCR1 CXCL8 CRP
5 pyelitis 31.5 UMOD TNF TLR4 LCN2 IL6 CXCR1
6 glomerulonephritis 31.4 LCN2 IL1B CCL2 ALB ACE
7 pyuria 31.3 LCN2 IL6 GPT CXCL8 CRP ALB
8 hydronephrosis 31.3 NAGLU IL6 CXCL8 CRP CCL2 AMBP
9 acute cystitis 31.2 UMOD TNF TLR4 LCN2 IL6 IL10
10 cholecystitis 31.1 TLR4 GPT ALB
11 fasciitis 31.1 TNF IL6 CXCL8
12 acute kidney failure 31.1 UMOD LCN2 GPT ALB
13 amyloidosis 31.0 TNF IL6 CRP ALB
14 necrotizing fasciitis 31.0 IL6 CXCL8 CRP ALB
15 toxic shock syndrome 31.0 TNF TLR4 IL6 IL1B IL10 CXCL8
16 nephrosclerosis 31.0 TNF CCL2 ACE
17 interstitial nephritis 30.9 UMOD CRP ALB ACE
18 splenic abscess 30.9 GPT CRP ALB
19 anuria 30.9 LCN2 CRP ALB ACE
20 prostatitis 30.8 TNF IL6 IL1B IL10 CXCL8
21 bacteriuria 30.8 UMOD TLR4 IL6 CXCR2 CXCR1 CXCL8
22 uremia 30.8 TNF IL6 CRP ALB ACE
23 emphysematous cholecystitis 30.8 GPT CRP
24 disseminated intravascular coagulation 30.8 TNF IL6 IL10 GPT CRP
25 endophthalmitis 30.8 TNF IL6 CXCL8 CRP ALB
26 endocarditis 30.7 TNF IL6 IL10 CXCL8 CRP ALB
27 diverticulitis 30.7 TNF IL6 CRP ALB
28 urinary tract obstruction 30.7 UMOD NAGLU LCN2 CRP CCL2 ALB
29 microvascular complications of diabetes 3 30.7 NAGLU ALB ACE
30 lung abscess 30.7 TNF IL6 CRP ALB
31 urethritis 30.7 TNF TLR4 IL6 CXCL8 CRP
32 posterior urethral valves 30.7 TNF IL6 ACE
33 spinal cord injury 30.7 TNF IL6 CXCL8
34 vaginal discharge 30.7 IL6 CXCL8 CRP
35 septic arthritis 30.6 TLR4 CXCL8 CRP CALCA
36 mycobacterium tuberculosis 1 30.6 TNF TLR4 IL10 CRP
37 eclampsia 30.5 TNF ALB ACE
38 deficiency anemia 30.5 TNF LCN2 IL6 CRP ALB ACE
39 autosomal dominant polycystic kidney disease 30.5 TNF LCN2 CCL2 ALB ACE
40 intestinal obstruction 30.5 IL6 GPT CRP ALB
41 polyarteritis nodosa 30.5 IL6 GPT CRP
42 infective endocarditis 30.5 TNF IL6 CRP
43 thrombocytosis 30.5 IL6 IL1B CRP ALB
44 haemophilus influenzae 30.5 TNF CXCL8
45 vasculitis 30.5 TNF LCN2 IL6 CRP CCL2
46 bronchiectasis 30.4 TNF IL6 CXCL8 CRP
47 vulvovaginitis 30.4 IL10 CXCL8 CCL5
48 aortitis 30.4 TNF IL6 CRP
49 systemic autoimmune disease 30.4 IL6 CRP
50 cellulitis 30.4 TNF IL6 IL10 CRP

Comorbidity relations with Pyelonephritis via Phenotypic Disease Network (PDN): (show all 20)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Cystitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Heart Disease Hydronephrosis
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Kidney Disease
Nephrolithiasis, X-Linked Recessive, with Renal Failure Osteoporosis
Paralytic Ileus Protein-Energy Malnutrition
Schizophreniform Disorder Ureterolithiasis

Graphical network of the top 20 diseases related to Pyelonephritis:



Diseases related to Pyelonephritis
Sources

Symptoms & Phenotypes for Pyelonephritis

About this section

GenomeRNAi Phenotypes related to Pyelonephritis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 ACE CXCL8 IL10 IL1B LCN2 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ACE CXCL8 IL10 IL1B LCN2 TNF

MGI Mouse Phenotypes related to Pyelonephritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 ACE ALB CRP CXCL2 CXCR2 IL10
2 immune system MP:0005387 10.13 ACE ALB CCL2 CCL5 CRP CXCR1
3 hematopoietic system MP:0005397 10.06 ACE CCL5 CXCR1 CXCR2 IL10 IL1B
4 liver/biliary system MP:0005370 9.81 ACE ALB CXCR2 IL10 IL6 LCN2
5 neoplasm MP:0002006 9.56 ACE ALB CXCR2 IL10 IL1B IL6
6 renal/urinary system MP:0005367 9.23 ACE ALB CXCR2 IL6 LCN2 NAGLU
Sources

Drugs & Therapeutics for Pyelonephritis

About this section

Drugs for Pyelonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4 58-05-9 6006 143
2
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
3
Sulfamethoxazole Approved Phase 4 723-46-6 5329
4
Fosfomycin Approved Phase 4 23155-02-4 446987
5
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
6
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
7
Methenamine Approved, Vet_approved Phase 4 100-97-0 4101
8
Norfloxacin Approved Phase 4 70458-96-7 4539
9
Acetaminophen Approved Phase 4 103-90-2 1983
10
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
11
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
12
Ofloxacin Approved Phase 4 82419-36-1 4583
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14 Folic Acid Antagonists Phase 4
15 Vitamin B9 Phase 4
16 Antimalarials Phase 4
17 Vitamin B Complex Phase 4
18 Antiparasitic Agents Phase 4
19 Folate Phase 4
20 Antiprotozoal Agents Phase 4
21 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
22 Lactams Phase 4
23 Amdinocillin Pivoxil Phase 4
24 Renal Agents Phase 4
25 Cytochrome P-450 Enzyme Inhibitors Phase 4
26 Anti-Infective Agents, Urinary Phase 4
27 Fluoroquinolones Phase 4
28 Methenamine mandelate Phase 4
29 Methenamine hippurate Phase 4
30 Pharmaceutical Solutions Phase 4
31 Anti-Inflammatory Agents Phase 4
32 Antipyretics Phase 4
33 Anti-Inflammatory Agents, Non-Steroidal Phase 4
34 Analgesics, Non-Narcotic Phase 4
35 Cyclooxygenase Inhibitors Phase 4
36 Antirheumatic Agents Phase 4
37 Analgesics Phase 4
38 Topoisomerase Inhibitors Phase 4
39 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
40
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
41
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
42
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
43
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
44 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
45
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
46
Racepinephrine Approved Phase 3 329-65-7 838
47
Sulbactam Approved Phase 3 68373-14-8
48
Vaborbactam Approved, Investigational Phase 3 1360457-46-0
49
Tigecycline Approved Phase 3 220620-09-7 5282044
50
Colistin Approved Phase 3 1066-17-7, 1264-72-8 5311054

Interventional clinical trials:

(show top 50) (show all 126)
# Name Status NCT ID Phase Drugs
1 Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis Unknown status NCT03179384 Phase 4 Ceftriaxone
2 Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old. Cefixime PO 10d vs Ceftriaxone IV 4d Followed by Cefixime PO 6d. Multicenter, Randomised Trial of Equivalence. Completed NCT00136656 Phase 4 antibiotic;antibiotics
3 Efficacy and Safety Study of Short Term Antibiotic During Seven Days With Ceftriaxone Intravenous the First Day Then Cefixime the Second Day Till the Seventh Day of Acute Uncomplicated Pyelonephritis in Women Between 18 and 65 Years Old Completed NCT01390623 Phase 4 Ceftriaxone
4 Antibiotic Prophylaxis After Acute Pyelonephritis for Prevention of Urinary Tract Infections in Children With Vesico-Ureteral Reflux. Completed NCT00382343 Phase 4 Sulfamethoxazole/trimethoprim
5 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication and Adherence in Emergency Ward Completed NCT02246361 Phase 4
6 Pharmacokinetics of Ciprofloxacin in Pediatric Patients With Emphasis on Renal Excretion Completed NCT02598362 Phase 4 ciprofloxacin
7 Randomized Controled Multicentric Trial, of Non Inferiority, Comparing Two Durations of Antibiotherapy (5 Days Versus 10 Days) in COMMUNAUTARY Acute Uncomplicated Pyelonephritis. Completed NCT00873626 Phase 4 levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)
8 Relevance of Biomarkers and Clinical Predictors of Outcome in Unselected Population With Febrile Urinary Tract Infection at Primary Care and Emergency Department in a Prospective, Randomized Cohort Trial Comparing Short (7 Days) Antibiotic Treatment With Conventional Treatment (14 Days) Completed NCT00809913 Phase 4 short treatment (ciprofloxacin)
9 Prospective, Open-Label, Noncomparative, Multicenter Study to Evaluate the Efficacy and Safety of Ciprofloxacin Extended Release (Cipro XR) 1000 mg Tablets Given Once Daily for 7 to 14 Days in the Treatment of Patients 18 Years or Older With Complicated Urinary Tract Infections Caused by Pseudomonas Aeruginosa and Other Common Uropathogens Completed NCT00481689 Phase 4 Cipro XR (Ciprofloxacin, BAYQ3939)
10 A Double-blind, Randomized, Placebo-controlled Phase IV Clinical Study of the Efficacy and Safety of a New Formulation of Paracetamol for the Management of Fever of Infectious Origin Completed NCT02283203 Phase 4 APOTEL max;Placebo
11 Perioperative Disodium Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients. Controlled Clinical Trial (PERIFOS Trial) Completed NCT03235947 Phase 4 Fosfomycin disodium;Trimethoprim / Sulfamethoxazole;Intravenous placebo
12 The Efficacy and Safety of Pivmecillinam in Treating Bacteriemic Urosepsis Caused by E.Coli Recruiting NCT03282006 Phase 4 pivmecillinam
13 Management of Sub-Clinical Bacteriuria in Pregnancy: A Feasibility Trial Recruiting NCT03275623 Phase 4 Antibiotic
14 Noroxin Efficacy and Safety Trial Not yet recruiting NCT03506256 Phase 4 Norfloxacin 400 MG
15 The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing Due to New Episodes of Urinary Tract Infections (UTI) in Elderly Women With Recurrent UTI - a Triple- Blinded, Randomized Placebo-controlled Phase IV Study Not yet recruiting NCT04077580 Phase 4 Methenamine Hippurate 1000 MG
16 Comparing the Efficacy of Intravenous Paracetamol and Ketoprofen When Treating Renal Colic in Emergency Situations: a Randomized, Bi-centric, Double-blind Controlled Trial Suspended NCT01685658 Phase 4 Intravenous ketoprofen;Intravenous paracetamol
17 TREATMENT OF ACUTE UNCOMPLICATED PYELONEPHRITIS WITH SHORT COURSE LEVOFLOXACIN A Pilot Study Terminated NCT00239161 Phase 4 Levofloxacin
18 Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL) Producing and AmpC Hyperproducing Enterobacteriaceae in United Kingdom Withdrawn NCT01543347 Phase 4 Temocillin
19 The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
20 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
21 To Study the Effect of Adjunctive Oral Methylprednisolone Therapy in Pediatric Urinary Tract Infection Unknown status NCT02331862 Phase 3 Methylprednisolone
22 A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) in Japanese Patients With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection Completed NCT02728089 Phase 3 MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
23 A Multicenter, Phase 3 Study of the Safety and Effectiveness of Doripenem in Complicated Lower Urinary Tract Infection or Pyelonephritis Completed NCT00210990 Phase 3 doripenem
24 A Multicenter, Double-Blind, Randomized, Phase 3 Study of Doripenem Verus a Comparator Antibiotic in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis Completed NCT00229021 Phase 3 doripenum
25 A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults Completed NCT01599806 Phase 3 Ceftazidime - Avibactam ( CAZ-AVI);Doripenem;Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
26 A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults Completed NCT01595438 Phase 3 Ceftazidime - Avibactam ( CAZ-AVI);Doripenem;Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
27 A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults Completed NCT02486627 Phase 3 plazomicin;meropenem;levofloxacin (oral)
28 A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis. Completed NCT00210886 Phase 3 levofloxacin
29 A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis Completed NCT01345929 Phase 3 CXA-201;Levofloxacin
30 Phase III, Randomized, Double-Blind, Study Evaluating Efficacy/Safety/Tolerability of Meropenem-Vaborbactam Compared to Piperacillin/Tazobactam in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis Completed NCT02166476 Phase 3 Meropenem-Vaborbactam;Piperacillin-Tazobactam;Levofloxacin;Saline
31 A Prospective, Multicenter, Noncomparative, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections Completed NCT00379951 Phase 3 ertapenem sodium
32 A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT01970371 Phase 3 plazomicin;colistin;meropenem;tigecycline;antibiotic of Investigator's choice
33 A Noncomparative, Multicenter, Open-Label, Study to Evaluate the Safety, Tolerability and Efficacy of MK0991 as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia Completed NCT00379964 Phase 3 caspofungin acetate
34 A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections Completed NCT03032510 Phase 3 Eravacycline;Ertapenem;Placebo;Levofloxacin
35 Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults Completed NCT02753946 Phase 2, Phase 3 ZTI-01;Piperacillin-tazobactam
36 A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT02168946 Phase 3 Vabomere;Best Available Therapy
37 Randomized, Double-blind, Double-dummy, Active-controlled, Multi-centre Trial to Compare the Efficacy and Safety of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) With Meropenem in Infections Caused by β-Lactamase (ESBL and MBL) Producing Gram-Negative Bacteria Completed NCT03477422 Phase 3 CSE-1034 (Ceftriaxone + Sulbactam + EDTA);Meropenem
38 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
39 A Double-blind Randomized Placebo-controlled Clinical Trial of the Safety and Efficacy of Intravenous Clarithromycin as Immunomodulatory Therapy for the Management of Sepsis Completed NCT01223690 Phase 3 Clarithromycin;Dextrose 5%
40 A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Recruiting NCT03788967 Phase 3 Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr);Ertapenem
41 A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis Recruiting NCT03840148 Phase 3 Cefepime/VNRX-5133;Meropenem
42 A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis. Recruiting NCT03687255 Phase 3 cefepime/AAI101 combination;Piperacillin/tazobactam
43 Evaluation of the Efficiency of Autologous Adipocytes Graft in Endoscopic Treatment in Vesico-Renal Reflux in Children Recruiting NCT00367159 Phase 3
44 A Double-Blind, Randomized, Placebo-Controlled Clinical Study of the Efficacy of Intravenous Clarithromycin as Adjunctive Treatment in Patients With Sepsis and Respiratory and Multiple Organ Dysfunction Syndrome Recruiting NCT03345992 Phase 3 Clarithromycin;Water for injection
45 A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem Followed by Optional Oral Therapy in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults Not yet recruiting NCT03630081 Phase 3 FEP-TAZ 4 g;Meropenem;ciprofloxacin 500 mg Optional Oral Switch
46 Randomised Controlled Trial on Efficacy and Safety of Short Term Versus Long Term Antibiotic Therapy for Pyelonephritis in Childhood. Terminated NCT00724256 Phase 3 ceftibuten;ceftibuten
47 A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infections Terminated NCT01110408 Phase 3 Doripenem;Doripenem placebo;Cefepime;Cefepime placebo;Amoxicillin/clavulanate potassium
48 A Phase 3, Randomized, Double-blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous Infusions of Flomoxef Versus Intravenous Infusions of Cefepime in the Treatment of Subjects With Complicated Urinary Tract Infections Including Pyelonephritis Terminated NCT02302092 Phase 3 Flomoxef;Cefepime
49 A Multicenter Randomized Controlled Trial of Antibiotic Treatment in Children With Urinary Tract Infections: Oral Amoxicillin/Clavulanic Acid Vs Initial Iv Ceftriaxone. Terminated NCT00161330 Phase 3 oral amoxicilline/clavulanic acid;iv ceftriaxone
50 A Randomized Controlled Trial of Antibiotic Prophylaxis in Children With Pyelonephritis in the Abscence of Vesicoureteral Reflux Withdrawn NCT00752375 Phase 3 Trimethoprim Sulfamethoxazole;placebo

Search NIH Clinical Center for Pyelonephritis

Cochrane evidence based reviews: pyelonephritis

Sources

Genetic Tests for Pyelonephritis

About this section

Genetic tests related to Pyelonephritis:

# Genetic test Affiliating Genes
1 Pyelonephritis 29
Sources

Anatomical Context for Pyelonephritis

About this section

MalaCards organs/tissues related to Pyelonephritis:

40
Kidney, Testes, Prostate, Liver, Colon, Neutrophil, Spinal Cord
Sources

Publications for Pyelonephritis

About this section

Articles related to Pyelonephritis:

(show top 50) (show all 12497)
# Title Authors PMID Year
1
Doripenem: a review of its use in the treatment of bacterial infections. 54 61
18778123 2008
2
Urinary N-acetyl-beta-D-glucosaminidase as a diagnostic marker of acute pyelonephritis in children. 54 61
19367005 2008
3
The multiple functions of Tamm-Horsfall protein in human health and disease: a mystery clears up. 54 61
15989109 2005
4
Tamm-Horsfall protein: a multilayered defence molecule against urinary tract infection. 54 61
15816991 2005
5
In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. 54 61
11801667 2002
6
Induction of innate immune responses by Escherichia coli and purified lipopolysaccharide correlate with organ- and cell-specific expression of Toll-like receptors within the human urinary tract. 54 61
11260138 2001
7
[Microproteinuria and enzymuria in fever and pyelonephritis in childhood. A prospective study of 180 children]. 54 61
9123685 1997
8
[Evaluation of N-acetyl-beta glucosaminidase in upper and lower urinary tract infections in childhood. Clinical study of 168 children]. 54 61
9064498 1996
9
dra-related X adhesins of gestational pyelonephritis-associated Escherichia coli recognize SCR-3 and SCR-4 domains of recombinant decay-accelerating factor. 54 61
7537246 1995
10
Urinary N-acetyl-beta-glucosaminidase and beta-2-microglobulin in the diagnosis of urinary tract infection in febrile infants. 54 61
8036046 1994
11
Urinary N-acetyl-beta-glucosaminidase in normal Chinese children and children with pyelonephritis. 54 61
2063674 1991
12
Urinary N-acetyl-beta-glucosaminidase and the selection of children for radiologic evaluation after urinary tract infection. 54 61
2371096 1990
13
The pathogenesis and management of renal scarring in children with vesicoureteric reflux and pyelonephritis. 61
30847554 2020
14
Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae. 61
31691817 2020
15
Ultrastructural evidence of the evolutional process in malakoplakia. 61
31298302 2020
16
Acidosis induces antimicrobial peptide expression and resistance to uropathogenic E. coli infection in kidney collecting duct cells via HIF-1α. 61
31841391 2020
17
Native valve infective endocarditis due to ampicillin-resistant Escherichia coli in the postoperative period of a right radical nephrectomy due to xanthogranulomatous pyelonephritis. 61
31757432 2020
18
Ovarian Vein Thrombosis in an Elderly Female with Pyelonephritis. 61
31401164 2020
19
Is Piperacillin-Tazobactam Really Comparable to Carbapenem for the Treatment of Pyelonephritis Caused by ESBL-producing Organisms? 61
32020164 2020
20
Pregnancy following urinary tract reconstruction using bowel segments: a review of published literature. 61
31028456 2020
21
Plazomicin: A New Aminoglycoside. 61
31328228 2020
22
Implementing A Root Cause Analysis Program To Enhance Patient Safety Education in Urology Residency. 61
31978526 2020
23
Causes of fever in pregnant women with acute undifferentiated fever: a prospective multicentric study. 61
31955353 2020
24
A systematic review of the clinical significance of nephrostomy urine cultures. 61
30734071 2020
25
Clinical and molecular analyses of bloodstream infections caused by IMP metallo-β-lactamase-producing Enterobacteriaceae in a tertiary hospital in Japan. 61
31427199 2020
26
Carbapenem-resistant Enterobacteriaceae: A retrospective review of treatment and outcomes in a long-term acute care hospital. 61
31431290 2020
27
Long-term Outcome of Renal Transplantation in Patients with Congenital Lower Urinary Tract Malformations: A Multicenter Study. 61
30964838 2020
28
Outcomes of ileal conduit urinary diversion in patients with multiple sclerosis. 61
31951678 2020
29
Case report: Xanthogranulomatous pyelonephritis masquerading as cystic renal cell carcinoma. 61
31976820 2020
30
Sarcomatoid chromophobe renal cell carcinoma revealed by acute pyelonephritis in a diabetic patient. 61
31681535 2020
31
Using the new definition of intraamniotic infection - is there morbidity among the women left out? 61
31928262 2020
32
Clinical, morphologic and histological features of chronic pyelonephritis: An 8-year review. 61
32003360 2020
33
Staphylococcus Aureus Osteomyelitis as an Inducer of Tolerance to Escherichia Coli Pyelonephritis: an Experimental Study. 61
31992837 2020
34
Diabetic ketoacidosis complicated by emphysematous pyelonephritis: a case report and literature review. 61
31996190 2020
35
Clinical outcome and prognostic factors of sepsis, septic shock and prolonged hospitalization, of patients presented with acute obstructive pyelonephritis. 61
32000528 2020
36
Evaluation of hematogenous spread and ascending infection in the pathogenesis of acute pyelonephritis due to group B streptococcus in mice. 61
31614193 2020
37
Stability and profiling of urinary microRNAs in healthy cats and cats with pyelonephritis or other urological conditions. 61
31721298 2020
38
Clinical effectiveness of oral antimicrobial therapy for acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales. 61
31520270 2020
39
Process Development and Synthesis of Process-Related Impurities of an Efficient Scale-Up Preparation of 5,2'-Dibromo-2,4',5'-Trihydroxy Diphenylmethanone as a New Acute Pyelonephritis Candidate Drug. 61
31979084 2020
40
Gas-containing renal stones. 61
31983832 2020
41
Renal actinomycosis presenting as uro-cutaneous fistula. 61
31709154 2020
42
Condition-specific surveillance in health care-associated urinary tract infections as a strategy to improve empirical antibiotic treatment: an epidemiological modelling study. 61
31555835 2020
43
Symptom- and urinalysis-based approach to diagnosing urinary tract infections in children with neuropathic bladders. 61
31919595 2020
44
Association of Antibiotic Treatment Duration With Recurrence of Uncomplicated Urinary Tract Infection in Pediatric Patients. 61
31958969 2020
45
Alpha-hemolysin of uropathogenic Escherichia coli induces GM-CSF-mediated acute kidney injury. 61
31719643 2020
46
Large floating thrombus in the inferior vena cava. 61
31983919 2020
47
Emphysematous Pyelonephritis: A single center review. 61
31933612 2020
48
Xanthogranulomatous Pyelonephritis with Direct Extension into the Liver. 61
31991112 2020
49
Potential Probiotics Bacillus subtilis KATMIRA1933 and Bacillus amyloliquefaciens B-1895 Co-Aggregate with Clinical Isolates of Proteus mirabilis and Prevent Biofilm Formation. 61
31989448 2020
50
Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. 61
31970713 2020
Sources

Variations for Pyelonephritis

About this section
Sources

Expression for Pyelonephritis

About this section
Search GEO for disease gene expression data for Pyelonephritis.
Sources

Pathways for Pyelonephritis

About this section

Pathways related to Pyelonephritis according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.1 TNF TLR4 LCN2 IL6 IL1B IL10
2
ERK Signaling 63
Show member pathways
 13.89 TNF IL6 IL1B IL10 CXCR2 CXCR1
3
PEDF Induced Signaling 63
Show member pathways
 13.75 TNF TLR4 IL6 IL1B IL10 CXCR2
4
Akt Signaling 63
Show member pathways
 13.49 TNF TLR4 IL6 IL1B IL10 CXCR2
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.44 TNF LCN2 IL6 IL1B IL10 CXCL8
6
PAK Pathway 63
Show member pathways
 13.38 TNF IL6 IL1B IL10 CXCR2 CXCR1
7
Toll-like Receptor Signaling Pathway 1 36
Show member pathways
 13.22 TNF TLR4 IL6 IL1B IL10 CXCL8
8
Human cytomegalovirus infection 36
Show member pathways
 13.03 TNF TLR4 IL6 IL1B CXCR2 CXCL8
9
CCR5 Pathway in Macrophages 63
Show member pathways
 12.95 CXCR2 CXCR1 CXCL8 CXCL2 CCL5 CCL2
10
Measles 36
Show member pathways
 12.91 TNF TLR4 IL6 IL1B CXCL8 CCL5
11
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 65
Show member pathways
 12.84 TNF TLR4 IL6 IL1B CXCL8 CCL5
12
Herpes simplex virus 1 infection 36
12.83 TNF IL6 IL1B CCL5 CCL2
13
T cell receptor signaling pathway 36
Show member pathways
 12.67 TNF TLR4 IL6 IL1B IL10
14
Th17 cell differentiation 36
Show member pathways
 12.66 TNF TLR4 IL6 IL1B IL10
15
Immune response IL-23 signaling pathway 22
Show member pathways
 12.65 TNF IL6 IL1B IL10 CCL2
16
NF-kappaB Signaling 4
12.63 TNF IL1B IL10 CCL5 CCL2
17
Insulin receptor recycling 65
Show member pathways
 12.58 LCN2 CXCR2 CXCR1 CXCL8 CXCL2 CCL5
18
Shigellosis 36
12.46 TNF TLR4 IL1B CXCL8 CCL5
19
IL-17 Family Signaling Pathways 64
Show member pathways
 12.45 TNF LCN2 IL6 IL1B CXCL8 CXCL2
20
Folate Metabolism 1
Show member pathways
 12.43 TNF IL6 IL1B CRP CCL5 CCL2
21
Toll Comparative Pathway 63
Show member pathways
 12.39 TNF TLR4 IL6 IL1B CXCL8
22
Pathogenic Escherichia coli infection 36
12.39 TNF TLR4 IL6 IL1B CXCL8
23
Immune response CCR3 signaling in eosinophils 22
Show member pathways
 12.38 CXCR2 CXCR1 CXCL8 CCL5
24
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.33 TNF IL6 IL1B IL10 CXCL8
25
Tuberculosis 36
12.33 TNF TLR4 IL6 IL1B IL10
26
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.32 TNF TLR4 IL6 CXCL8
27
Toxoplasmosis 36
Show member pathways
 12.31 TNF TLR4 IL1B IL10
28
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.31 TNF IL6 IL10 CXCR2 CXCR1 CXCL8
29
Bacterial infections in CF airways 22
Show member pathways
 12.29 TNF TLR4 IL6 IL1B CXCL8
30
IL-1 Family Signaling Pathways 64
Show member pathways
 12.28 TNF IL6 IL1B CXCL8
31
C-type lectin receptor signaling pathway 36
Show member pathways
 12.27 TNF IL6 IL1B IL10
32
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.27 TNF IL6 IL1B IL10 CXCL8
33
NOD-like receptor signaling pathway 36
12.23 TNF TLR4 IL6 IL1B CXCL8 CXCL2
34
Th1 Differentiation Pathway 64
Show member pathways
 12.16 TNF TLR4 IL6 IL1B IL10
35
Microglia Activation During Neuroinflammation: Overview 64
Show member pathways
 12.11 TNF TLR4 IL6 IL1B
36
TNF signaling pathway 36
12.1 TNF IL6 IL1B CXCL2 CCL5 CCL2
37
Yersinia infection 36
12.1 TNF TLR4 IL6 IL1B IL10 CXCL8
38
Spinal Cord Injury 1
12.08 TNF TLR4 IL6 IL1B CXCL8 CXCL2
39
NF-kappa B signaling pathway 36
12.04 TNF TLR4 IL1B CXCL8 CXCL2
40
AGE-RAGE signaling pathway in diabetic complications 36
12.03 TNF IL6 IL1B CXCL8 CCL2
41
Interleukin-4 and 13 signaling 65
12.03 TNF LCN2 IL6 IL1B IL10 CXCL8
42
Amoebiasis 36
11.96 TNF TLR4 IL6 IL1B IL10 CXCL8
43
Salmonella infection (KEGG) 36
11.91 TLR4 IL6 IL1B CXCL8 CXCL2
44
Pertussis 36
11.88 TNF TLR4 IL6 IL1B IL10 CXCL8
45
Dendritic Cells Developmental Lineage Pathway 64
11.85 TNF IL6 IL1B IL10
46
Microglia Activation During Neuroinflammation: Microglia Polarization 64
11.84 TNF IL6 IL1B IL10 CCL5 CCL2
47
Innate Lymphoid Cell Differentiation Pathways 64
11.82 TNF IL1B IL10
48
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.79 TNF IL6 IL1B CXCL8 CXCL2
49
Legionellosis 36
11.73 TNF TLR4 IL6 IL1B CXCL8 CXCL2
50
Rheumatoid arthritis 36
11.73 TNF TLR4 IL6 IL1B CXCL8 CXCL2
Sources

GO Terms for Pyelonephritis

About this section

Cellular components related to Pyelonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 UMOD TNF LCN2 IL6 IL1B IL10
2 cell GO:0005623 9.8 LCN2 IL6 CXCR2 CXCR1 CCL5 CCL2
3 external side of plasma membrane GO:0009897 9.55 TNF TLR4 CXCR2 CXCR1 ACE
4 extracellular space GO:0005615 9.5 TNF LCN2 IL6 IL1B IL10 GPT

Biological processes related to Pyelonephritis according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.33 TLR4 IL6 IL1B IL10 CXCR2 CXCR1
2 G protein-coupled receptor signaling pathway GO:0007186 10.26 CXCR2 CXCR1 CXCL8 CXCL2 CCL5 CCL2
3 positive regulation of gene expression GO:0010628 10.12 TNF TLR4 LCN2 IL6 IL1B CRP
4 negative regulation of cell proliferation GO:0008285 10.11 UMOD IL6 IL1B IL10 CXCL8
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.02 TNF TLR4 CCL5 CCL2
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 TNF TLR4 IL6 IL1B
7 cytokine-mediated signaling pathway GO:0019221 9.97 TNF LCN2 IL6 IL1B IL10 CXCL8
8 positive regulation of DNA-binding transcription factor activity GO:0051091 9.96 TNF IL6 IL1B IL10
9 cellular response to tumor necrosis factor GO:0071356 9.96 LCN2 CXCL8 CCL5 CCL2 CALCA
10 cellular response to interleukin-1 GO:0071347 9.93 LCN2 CXCL8 CCL5 CCL2
11 chemotaxis GO:0006935 9.91 CXCR2 CXCR1 CXCL8 CXCL2 CCL5 CCL2
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 TNF IL6 CCL5
13 cellular response to organic cyclic compound GO:0071407 9.9 TNF IL1B CCL5 CCL2
14 immune response GO:0006955 9.9 TNF TLR4 IL6 IL1B IL10 CXCR2
15 regulation of insulin secretion GO:0050796 9.89 TNF IL1B CCL5
16 response to glucocorticoid GO:0051384 9.89 TNF IL6 IL10
17 positive regulation of interleukin-6 production GO:0032755 9.89 TNF TLR4 IL6 IL1B
18 positive regulation of T cell proliferation GO:0042102 9.88 IL6 IL1B CCL5
19 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TNF TLR4 IL1B
20 positive regulation of smooth muscle cell proliferation GO:0048661 9.88 TNF IL6 CCL5
21 cell chemotaxis GO:0060326 9.88 CXCR2 CXCR1 CXCL2 CCL5 CCL2
22 humoral immune response GO:0006959 9.87 TNF IL6 CCL2
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 TNF TLR4 IL1B
24 positive regulation of interferon-gamma production GO:0032729 9.86 TNF TLR4 IL1B
25 negative regulation of interleukin-6 production GO:0032715 9.85 TNF TLR4 IL10
26 positive regulation of interleukin-6 secretion GO:2000778 9.85 TNF TLR4 IL1B
27 chemokine-mediated signaling pathway GO:0070098 9.85 CXCR2 CXCR1 CXCL8 CXCL2 CCL5 CCL2
28 cellular response to fibroblast growth factor stimulus GO:0044344 9.84 CXCL8 CCL5 CCL2
29 monocyte chemotaxis GO:0002548 9.84 IL6 CCL5 CCL2 CALCA
30 leukocyte cell-cell adhesion GO:0007159 9.83 UMOD CCL5 CALCA
31 negative regulation of neurogenesis GO:0050768 9.83 TNF IL6 IL1B
32 receptor internalization GO:0031623 9.83 CXCR2 CXCR1 CXCL8 CALCA
33 leukocyte chemotaxis GO:0030595 9.81 IL10 CXCL8 CXCL2
34 protein kinase B signaling GO:0043491 9.81 TNF IL1B CCL5 CCL2
35 positive regulation of chemokine production GO:0032722 9.8 TNF TLR4 IL6
36 positive regulation of JAK-STAT cascade GO:0046427 9.8 TNF IL6 IL10 CCL5
37 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 TNF TLR4 IL1B CCL5 CCL2
38 neutrophil chemotaxis GO:0030593 9.8 IL1B CXCR2 CXCR1 CXCL8 CXCL2 CCL5
39 positive regulation of glial cell proliferation GO:0060252 9.79 TNF IL6 IL1B
40 dendritic cell chemotaxis GO:0002407 9.79 CXCR2 CXCR1 CCL5
41 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.78 TNF IL1B IL10
42 positive regulation of neuroinflammatory response GO:0150078 9.76 TNF IL6 IL1B
43 positive regulation of interleukin-8 production GO:0032757 9.76 TNF TLR4 IL1B CALCA
44 neutrophil activation GO:0042119 9.75 CXCR2 CXCL8 CCL5
45 response to molecule of bacterial origin GO:0002237 9.74 IL10 CXCL8 CXCL2
46 positive regulation of MHC class II biosynthetic process GO:0045348 9.73 TLR4 IL10
47 negative regulation of lipid storage GO:0010888 9.72 TNF IL6 CRP
48 endothelial cell apoptotic process GO:0072577 9.71 TNF IL10
49 neutrophil mediated immunity GO:0002446 9.71 IL6 ACE
50 regulation of establishment of endothelial barrier GO:1903140 9.7 TNF IL1B

Molecular functions related to Pyelonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 C-X-C chemokine receptor activity GO:0016494 9.37 CXCR2 CXCR1
2 interleukin-8 binding GO:0019959 9.32 CXCR2 CXCR1
3 enterobactin binding GO:1903981 9.26 LCN2 ALB
4 chemokine activity GO:0008009 9.26 CXCL8 CXCL2 CCL5 CCL2
5 cytokine activity GO:0005125 9.23 TNF IL6 IL1B IL10 CXCL8 CXCL2
6 interleukin-8 receptor activity GO:0004918 9.16 CXCR2 CXCR1
Sources

Sources for Pyelonephritis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....